OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a research report issued on Monday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Stock Up 2.5 %

Shares of NASDAQ OPGN opened at $0.61 on Monday. OpGen has a 52 week low of $0.17 and a 52 week high of $3.84. The business has a 50-day simple moving average of $0.57 and a two-hundred day simple moving average of $0.51. The company has a market cap of $7.74 million, a P/E ratio of -0.09 and a beta of -0.71.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.